Back to Search
BRIDGET FINDLAY, MD
MD
Urology Physician
NPI: 1649736851IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
73905(AZ)67873(MN)
CMS Specialties
PrimaryUROLOGY
Education
RUTGERS, ROBERT WOOOD JOHNSON MEDICAL SCHOOL
Class of 2019
Research & Publications (20)
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
PMID 19666851·J Natl Cancer Inst·2009
8-other
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
PMID 19001325·J Clin Oncol·2008
4-observational
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
PMID 17878480·J Clin Oncol·2007
3-trial
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
PMID 17716984·Ann Oncol·2007
3-trial
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
PMID 17687151·J Clin Oncol·2007
4-observational
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
PMID 17559146·Cancer·2007
4-observational
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
PMID 16849748·J Clin Oncol·2006
4-observational
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
PMID 16822845·J Clin Oncol·2006
4-observational
Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer.
PMID 15941948·Cancer Epidemiol Biomarkers Prev·2005
8-other
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
PMID 15677624·Ann Oncol·2005
3-trial
Operationalizing the concept of the optimal healing environment in clinical settings: the importance of "readiness".
PMID 15630829·J Altern Complement Med·2004
6-review
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
PMID 15470715·Cancer·2004
3-trial
From parallel practice to integrative health care: a conceptual framework.
PMID 15230977·BMC Health Serv Res·2004
4-observational
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
PMID 14665611·J Clin Oncol·2004
3-trial
Evaluation of the Tzu Chi Institute for Complementary and Alternative Medicine's Integrative Care Program.
PMID 14499036·J Altern Complement Med·2003
8-other
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
PMID 12837810·J Clin Oncol·2003
3-trial
Maturation of complementary and alternative healthcare in Canada.
PMID 12811078·Healthc Pap·2003
8-other
The Cull report: requiring health providers to report complaints.
PMID 11587308·N Z Med J·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1649736851
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 7
- Publications
- 20
Are you this provider?
Claim Your Profile